Oncolytics Biotech Inc T.ONC

Alternate Symbol(s): ONCY

Healthcare Biotechnology

Oncolytics Biotech Inc. is a biotechnology company. The Company is focused on developing pelareorep, an intravenously delivered immunotherapeutic agent that activates the innate and adaptive immune systems and weakens tumor defense mechanisms. This compound induces anti-cancer immune responses and promotes an inflamed tumor phenotype turning cold tumors hot through innate and adaptive immune responses to treat a variety of cancers. This improves the ability of the immune system to fight cancer, making tumors more susceptible to a broad range of oncology treatments. The Company’s primary focus is to advance its programs in hormone receptor-positive / human epidermal growth factor 2- negative (HR+/HER2-) metastatic breast cancer and advanced/metastatic pancreatic ductal adenocarcinoma to phase 3 licensure-enabling studies. In addition, it is exploring opportunities for registrational programs in other gastrointestinal cancers through its GOBLET platform study.

TSX:ONC - Post by User

Oncolytics Biotech Inc

<< Previous

Bullboard Posts

Next >>

Post by SundayMovieson Mar 08, 2023 9:36am

153 Views

Post# 35325535

Hostile Take Over - Part III

Why would someone do this?

Well, it's cheap and easy.

So, you offer let's 200 millions for all the outstanding shares. 2 times current market cap, all shareholders would have to fold.

You inject another 30 millions to finish the trial. Then you have a world class, plateform drug for peanuts. You could also licensing it out again.

There is virtually no defense here.

So, if the SP goes down, the higher likelyhood we get an hostile take-over. Until data is release or market properly price this stock, a hostile takeover makes a whole lot of sense for an acquiror.